# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 ...
Tecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis i...
Cadrenal Therapeutics (NASDAQ:CVKD) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cadrenal Therapeutics (NASDAQ:CVKD) with a Buy and maintains $3 ...
FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for...